Company intelligence / Profile preview

Hansoh BioMedical R&D Company

Lianyungang, Jiangsu, China

Ownership: Private
Employees: ~10000
Development stage: Other

Overview

Hansoh Pharma is a major Chinese biopharma company, listed on the HKSE, with over seven marketed innovative drugs, more than 40 clinical drug candidates, leading modalities in small molecule, ADC, siRNA, peptides, and robust partnerships, with most revenue now driven by innovative drugs. Recent approvals include first-in-class drugs for renal anaemia, third-gen EGFR-TKI, CD19 mAb for NMOSD, and oral hepatitis B agents.

Therapeutic areas: EndocrinologyNephrologyInfectious DiseasesOncologyNeurology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateSynthetic peptideShort interfering RNABispecific monoclonal antibodyFusion proteinNanoformulation
Industry: Pharma

Partnerships

GSKMSD (Merck)RegeneronMerck (HS-10535 license)

Beyond the preview

Go deeper on Hansoh BioMedical R&D Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hansoh BioMedical R&D Company.

Explore the full profile